Last updated: 2026-09-12 19:57:20. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Alto Neuroscience Inc. (ANRO) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NYSE. The stock is currently priced at $32.02, with a market capitalization of $1.24B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $3.59 to $37.48. This page covers its latest market performance, valuation, price trends and company information.
$1.24B | |
$32.00 | |
$37.48 | |
$1.60 | |
$31.68 | |
341.90K | |
550.79K | |
-- | |
$37.48 | |
$3.59 | |
-- | |
-- |
Alto Neuroscience Inc. (ANRO) last closed at $31.68 as of 2026-09-11 23:31:00, unchanged from the previous close of $31.68.
During the latest regular trading session, ANRO traded between $1.60 and $37.48, with a volume of 341.90K shares. The closing price was near the upper end and near the upper end of its 52-week range.
Over the past seven days, Alto Neuroscience Inc. (ANRO) moved from $36.64 to $32.02, representing a decline of 12.61% ($4.62).
The stock traded between $31.00 and $37.39 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 481.57 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 83.9%
ANRO is currently trading at $32.02, placing it 83.9% of the way from its 52-week low of $3.59 to its 52-week high of $37.48. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Alto Neuroscience Inc is a clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging individual's neurobiology to develop personalized and effective treatment options. The company currently consists of different clinical-stage assets such as ALTO-100, ALTO-202, ALTO-207, ALTO-101, and ALTO-300 among others initially targeting depressive disorders and schizophrenia populations as identified by independent brain-based biomarkers.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 68 |
| Exchange | NYSE |
| Company Website |
Eligible investors can buy real shares of Alto Neuroscience Inc. (ANRO) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.